Vimarsana
Biggest News Aggregation in the World

Alectin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alectin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alectin Today - Breaking & Trending Today

GALECTIN THERAPEUTICS INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Vimarsana News

GALECTIN THERAPEUTICS INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)

Item 2.02 Results of Operations and Financial Condition. On March 30, 3023, Galectin Therapeutics Inc. issued a press release announcing its results of operations and financial condition as of and... | March 30, 2023

Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer - Vimarsana News

Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer

NORCROSS, Ga., Oct. 12, 2022 -- Galectin Therapeutics, Inc. , the leading developer of therapeutics that target galectin-3, today announced that its Investigational New Drug application for... | October 12, 2022

"Overcoming microenvironment-mediated chemoprotection through stromal g" by Somayeh S. Tarighat, Fei Fei et al. - Vimarsana News

"Overcoming microenvironment-mediated chemoprotection through stromal g" by Somayeh S. Tarighat, Fei Fei et al.

Environmentally-mediated drug resistance in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) significantly contributes to relapse. Stromal cells in the bone marrow environment protect leukemia cells by secretion of chemokines as cues for BCP-ALL migration towards, and adhesion to, stroma. Stromal cells and BCP-ALL cells communicate through stromal galectin-3. Here, we investigated the significance of stromal galectin-3 to BCP-ALL cells. We used CRISPR/Cas9 genome editing to ablate galectin-3 in stromal cells and found that galectin-3 is dispensable for steady-state BCP-ALL proliferation...

Source: uow.edu.au